Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

Activity of Selinexor As a Single Agent and Synergistic Activity with Approved/Investigational Myelofibrosis Therapies in Vitro

Marie E E Maloof, Stephen Wu, Andrea Ellero, Christopher J Walker, Steve Kye, Pietro Taverna

Blood (2023) 142 (Supplement 1): 6353.

https://doi.org/10.1182/blood-2023-180134

Published: 2023

Journal Articles

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Blood (2022) 140 (Supplement 1): 1523–1525.

https://doi.org/10.1182/blood-2022-159409

Published: 2022

Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer

Blood (2022) 139 (6): 859–875.

https://doi.org/10.1182/blood.2021011516

Published: 2022

Includes: Supplemental data

Journal Articles

Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib

Blood (2021) 138 (Supplement 1): 906.

https://doi.org/10.1182/blood-2021-151073

Published: 2021

Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Blood (2021) 138 (Supplement 1): 2568.

https://doi.org/10.1182/blood-2021-152267

Published: 2021

Journal Articles

Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease

Kamira Maharaj, Melanie Mediavilla-Varela, Angimar Uriepero, Judith A. Fox, Pietro Taverna, Wael Gamal, Eva Sahakian, Javier Pinilla Ibarz

Blood (2021) 138 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2021-150598

Published: 2021

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

John N. Allan, MD, William G. Wierda, MD PhD, Krish Patel, MD, Susan M. O'Brien, MD, Anthony R Mato, MD, Matthew S Davids, Richard R. Furman, MD, John M. Pagel, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Pietro Taverna, PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2018-99-116382

Published: 2018

Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD

Blood (2018) 132 (Supplement 1): 584.

https://doi.org/10.1182/blood-2018-99-114027

Published: 2018

Journal Articles

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, Eugen Tausch, MD, Judith A. Fox, PhD, Pietro Taverna, PhD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2018-99-116664

Published: 2018

Journal Articles

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Patricia L. Kropf, MD, Woonbok Chung, PhD, Andrew D. Kelly, BA, Hagop M. Kantarjian, MD, Gail J. Roboz, Karen W.L. Yee, MD, Pietro Taverna, PhD, Sue Naim, Mohammad Azab, MD, Jaroslav Jelinek, MD PhD, Jean-Pierre J. Issa, MD

Blood (2016) 128 (22): 1680.

https://doi.org/10.1182/blood.V128.22.1680.1680

Published: 2016

Journal Articles

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

Guillermo Garcia-Manero, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Xiaoping Zhang, PhD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 114.

https://doi.org/10.1182/blood.V128.22.114.114

Published: 2016

Journal Articles

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Srikanth Gottipati, PhD, Shashank Rohatagi, PhD, Woonbok Chung, PhD, Pietro Taverna, PhD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD

Blood (2015) 126 (23): 2594.

https://doi.org/10.1182/blood.V126.23.2594.2594

Published: 2015

Journal Articles

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Michael R. Savona, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Wael A. Harb, MD, Amy E. DeZern, MD MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Richa Dua, PharmD, Roya Nawabi, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 1683.

https://doi.org/10.1182/blood.V126.23.1683.1683

Published: 2015

Journal Articles

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Blood (2015) 126 (23): 458.

https://doi.org/10.1182/blood.V126.23.458.458

Published: 2015

Journal Articles

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Kristen A Palmer, Maxwell D Coll, Michal Bar-Natan, MD, Hasan Rajabi, PhD, Poorvi Somaiya, MSc, Katarina Luptakova, MD, Salvia Jain, MD, Malgorzata McMasters, MD, James D. Levine, MD, Jon Arnason, MD, Pietro Taverna, PhD, Donald Kufe, MD, David Avigan, MD, Jacalyn Rosenblatt, MD

Blood (2014) 124 (21): 2303.

https://doi.org/10.1182/blood.V124.21.2303.2303

Published: 2014

Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2014) 124 (21): 529.

https://doi.org/10.1182/blood.V124.21.529.529

Published: 2014

Journal Articles

Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML)

Simone Jueliger, PhD, John F Lyons, PhD, Joern Lewin, PhD, Mohammad Azab, MD, Pietro Taverna, PhD

Blood (2014) 124 (21): 1050.

https://doi.org/10.1182/blood.V124.21.1050.1050

Published: 2014

NARROW

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Activity of Selinexor As a Single Agent and Synergistic Activity with Approved/Investigational Myelofibrosis Therapies in Vitro

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only